Suchergebnisse - "Davies, Jane C"

PubPharm (27)

1

Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial

enthalten in: American journal of respiratory and critical care medicine | 2023

von McNally, P. | Lester, K. | Stone, G. | +25

CommentIn: Am J Respir Crit Care Med. 2023 Nov 1;208(9):911-913. - PMID 37756441

2

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One F508del Allele : A Phase 3, Open-Label Clinical Trial

enthalten in: American journal of respiratory and critical care medicine | 2023

von Wainwright, C. | McColley, S. | McNally, P. | +14

CommentIn: Am J Respir Crit Care Med. 2023 Jul 1;208(1):9-11. - PMID 37167625

3

Raised Intracranial Pressure in Three Children with Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor Modulator Therapy

enthalten in: American journal of respiratory and critical care medicine | 2023

von Southern, K. | Barben, J. | Goldring, S. | +5

4

Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation : A Phase 3b, Randomized, Placebo-controlled Study

enthalten in: American journal of respiratory and critical care medicine | 2022

von Mall, M. | Brugha, R. | Gartner, S. | +21

CommentIn: Am J Respir Crit Care Med. 2022 Dec 1;206(11):1308-1310. - PMID 35947636

5

A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2022

von Sawicki, G. | Chilvers, M. | McNamara, J. | +10

6

An Update on CFTR Modulators as New Therapies for Cystic Fibrosis

enthalten in: Paediatric drugs | 2022

von King, J. | Nichols, A. | Bentley, S. | +2

7

COUNTERPOINT : In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? No

enthalten in: Chest | 2022

von Thursfield, R. | Shafi, N. | Davies, J.

CommentOn: Chest. 2022 Jan;161(1):18-20. - PMID 35000701

8

Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation : a phase 3, open-label, extension study

enthalten in: The Lancet. Respiratory medicine | 2021

von Chilvers, M. | Davies, J. | Milla, C. | +5

ErratumIn: Lancet Respir Med. 2021 Apr;9(4):e38. - PMID 33607008

9

Ivacaftor in People with Cystic Fibrosis and a 3849+10kb C→T or D1152H Residual Function Mutation

enthalten in: Annals of the American Thoracic Society | 2021

von Kerem, E. | Cohen-Cymberknoh, M. | Tsabari, R. | +13

10

Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial

enthalten in: American journal of respiratory and critical care medicine | 2021

von Davies, J. | Wainwright, C. | Sawicki, G. | +7

CommentIn: Am J Respir Crit Care Med. 2021 Mar 1;203(5):536-537. - PMID 33113333